ELAPRASE

Is now approved and launched in 43 countries.

“Since I started taking ELAPRASE, I have more energy to enjoy things that I wouldn't have been able to, and this has made my life better.”
Andrew Watkins

ELAPRASE is the first and only enzyme replacement therapy for Hunter syndrome-a rare, progressive and life-threatening condition that primarily affects boys. For more information on Shire products visit http://www.shire.com/shire/products/

Focus on the science - HGT

From science to sales

We have a delivery model that reflects the different market dynamics of our two businesses, and helps us meet our patients' needs more effectively.